The liver fibrosis treatment market primarily deals with therapeutic drugs and techniques used to cure liver fibrosis or scarring. Liver fibrosis occurs due to prolonged damage to the liver tissues caused by conditions like non-alcoholic fatty liver disease, alcohol abuse, viral hepatitis, autoimmune hepatitis, etc. This injury triggers the liver cells to deposit excess collagen fibers leading to scarring. Therapies for liver fibrosis include antifibrotic drugs, antiviral medications for hepatitis infections, blood thinners and treatment of underlying disorders.
The global liver fibrosis treatment market size is estimated to be valued at US$ 18.77 Mn in 2024 and is expected to exhibit a CAGR of 4.9% over the forecast period 2024 to 2030.
Liver fibrosis drugs are used to reverse the scarring and restore normal liver functions. They help reduce collagen deposition and boost collagen breakdown. Key antifibrotic medications include interferon gamma-1b injections, collagen cross-linking agents and FXR agonists. With growing prevalence of chronic liver diseases worldwide, the demand for liver fibrosis drugs is increasing steadily. Telemedicine has emerged as an important medium for managing liver-related conditions amid lockdowns and restrictions imposed due to the Covid-19 pandemic. This is expected to drive further growth in the market over the next few years.
Key Takeaways
Key players operating in the Liver Fibrosis Treatment Market Size are Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, DANONE S.A., B.Braun Melsungen AG, Mead Johnson & Company, LLC, Perrigo Company PLC, Koru Nutrition Inc., and Koninklijke DSM N.V. Key players are focusing on developing newer antifibrotic therapies with higher efficacy and less side effects.
The global burden of chronic liver diseases including viral hepatitis, non-alcoholic fatty liver disease and alcohol-induced liver damage is rising continuously. This spike in underlying conditions is fueling the demand for liver fibrosis treatment drugs and therapies.
Several companies are also expanding their geographical presence in emerging markets of Asia Pacific, Latin America, Middle East and Africa to tap the growth opportunities in these regions. Supported by improvement in diagnosis and management of chronic liver conditions, the global liver fibrosis treatment market is projected to witness substantial gains.
Market key trends
One of the major trends in the liver fibrosis treatment market is the increasing adoption of telemedicine for managing chronic liver conditions amidst COVID-19. Many healthcare providers have started offering telemedicine services for liver disease patients that include video/phone consultations with hepatologists, delivery of antifibrotic drugs at doorstep and remote monitoring. This enables continuity of treatment while reducing risk of infection transmission. It has augmented access to fibrosis care especially in regions where specialist care was limited earlier. The telemedicine approach is expected to remain integral to liver disease management even post pandemic due to associated benefits.
Porter’s Analysis
Threat of new entrants: Low barriers allow for new companies to enter the market easily. However, established brands have significant customer loyalty and economies of scale.
Bargaining power of buyers: Large buyers such as hospitals can negotiate lower prices from suppliers due to their high purchase volumes. Individual consumers have relatively low bargaining power.
Bargaining power of suppliers: Few key suppliers for major raw materials exert bargaining power over manufacturers through their ability to raise prices or reduce quality. There is a constant need to search for new suppliers.
Threat of new substitutes: Potential alternatives emerging through research & development could pose a threat by meeting needs better or at lower prices.
Competitive rivalry: Intense competition exists among the major players to gain market share through product differentiation, marketing initiatives, and competitive pricing.
Geographical Regions
North America accounts for the largest share of the liver fibrosis treatment market, owing to the high prevalence of non-alcoholic fatty liver disease and well-developed healthcare infrastructure. Asia Pacific has emerged as the fastest growing regional market due to rising obesity rates, growing geriatric population, increasing healthcare expenditure, and improving access to diagnosis and treatment in countries such as China, India, and Japan.
For more Insights, Read –
https://www.newswirestats.com/liver-fibrosis-treatment-market-trends-size-and-share-analysis
Chronic liver disease, on the other hand, occurs over time, sometimes due to a reaction to certain medications or a mild genetic enzyme deficiency.
The two types of the disease are separated by a difference in symptoms, severity, and the treatment of the disease.The possible treatment options for liver fibrosis comprise the use of therapeutic immunosuppressive agents, surgical removal or dissolution of an obstruction in the bile channel, change in diet, lifestyle modifications like lower intake of alcohol and cholesterol, control of blood sugar and lipid levels, and even medications for symptomatic treatment.
Therapy options include combinations of pharmacological, nutritional, surgical, or complementary and alternative treatments.
For example, the Ayurvedic combination of Gastrodiazza (Moringa pteridosperms), Kutki (Picrorrhiza kurroa), Shatavari (Asparagus racemosus), Abhrak Bhasma, Suvarna Bhasma, Yashtimadhuk (Glycyrrhiza glabra), Chandan (Santalum album), Manjishtha (Rubia cordifolia), Saraiva (Hemidesmus indicus), Haridra (Curcuma longa), Amalaki (Emblica Officinalis), Patol (Tricosanthe dioica), Patha (Cissampelos pareira), Musta (Cyperus rotundus) and Nimba (Azadirachta indica).
This combination includes chemotherapy with carboplatin, bromocriptine, methotrexate, cisplatin, vincristine, vinblastine, gemcitabine, intravenous immunoglobulin, vitamin K, methotrexate, or combination treatment.
The combination of these two drugs reduces the amount of protein produced by the liver and thus prevents or delays the progression of liver fibrosis.
